Our firm is investigating cases involving individuals who have taken the weight-loss drug Saxenda and subsequently been diagnosed with pancreatic cancer.
The U.S. Food & Drug Administration (“FDA”) approved the drug for weight-loss in 2014. While the single-dose Saxenda “injection pen” carries a strong, “black-box” warning for certain types of thyroid cancer (C-cell tumors), there is nothing in Saxenda’s labeling about an increased risk for pancreatic cancer. People using Saxenda should seek immediate medical attention if they develop severe abdominal pain, stomach pain that does not go away (with or without vomiting), or pain that spreads from the stomach to the back.
If you or a loved one have taken Saxenda injections and subsequently been diagnosed with Pancreatic Cancer contact us online or call 1-866-252-3535 for a free consultation.